Professor Richard Eastell
MD FRCP FRCPI FRCPEdin FRCPath FMedSci
Department of Oncology and Metabolism
Professor of Bone Metabolism
Director of the Mellanby Centre for Bone Research
+44 114 215 9006
Full contact details
Department of Oncology and Metabolism
Metabolic Bone Centre, Sorby Wing
Northern General Hospital
I received a clinical fellowship from the Medical Research Council to study osteoporosis at the University of Edinburgh in 1978. I furthered my clinical research training by working at the Mayo Clinic under the supervision of Dr B L Riggs where I worked for five years. I developed a number of new approaches for studying osteoporosis while at the Mayo Clinic including the use of stable (non-radioactive) isotopes to measure the absorption of calcium from food, the use of an infusion technique to measure the production of the active form of vitamin D, the measurement of bone density at the site in the wrist where fractures commonly occur (the ultradistal radius) and a height ratio approach to identifying vertebral fractures on radiographs of the spine. I began my training in endocrinology and diabetes at the Western General Hospital in Edinburgh in 1980 and continued it at Northwick Park Hospital in Harrow in 1982 and at the Mayo Clinic in 1987.
I joined the Department of Human Metabolism and Clinical Biochemistry at the University of Sheffield in 1989 as a Senior Research Fellow. I set up a metabolic bone service at the Northern General Hospital and am an Honorary NHS Consultant. I became Professor of Bone Metabolism in 1995 and received funding from the Arthritis Research Campaign to use biochemical tests of bone turnover to better understand the way in which older men and women develop osteoporosis and propensity to fracture.
My studies on the cause, diagnosis, prevention and treatment of osteoporosis have been conducted with the support of many colleagues; I have supervised the study for 37 doctoral degrees over the past 30 years. I have published over 550 research papers.
I am currently Director of the Mellanby Centre based at the University of Sheffield. I became an NIHR Senior Investigator in 2009. Some of my recent contributions have been authorship on key papers describing new treatments for osteoporosis, such as tibolone, zoledronic acid, denosumab and lasofoxifene as well as addressing issues about safety of medications and provide guidelines to diagnose primary hyperparathyroidism, a common disorder resulting in high levels of blood calcium.
My work as a clinical investigator was recognised in 2014, by the Frederick C Bartter Award from the American Society for Bone and Mineral Research.
- Research interests
My research focus is osteoporosis. The University of Sheffield is well regarded for its contribution to the study of osteoporosis. I have been ranked the third most highly-cited researcher in the world in the field of osteoporosis (Pluskiewicz W, et al. Arch Osteoporos. 2018 Mar 26;13(1):35). I study the epidemiology, pathogenesis, diagnosis and treatment of the disease. This has involved developing and establishing assays for bone turnover markers and studying their clinical utility. I have developed new approaches to the definition of vertebral fracture and applied new approaches such as vertebral fracture assessment. I have developed tools to evaluate bone strength such as high-resolution quantitative computed tomography, ultrasound and finite element modelling of bone strength. I have evaluated the endocrine changes in osteoporosis to better understand its causes. I have designed and conducted clinical trials of nutrition and drugs for the prevention and treatment of osteoporosis. I have evaluated approaches to enhance compliance with treatment.
• Anabolic effects of teriparatide on bone
• The onset and offset of bisphosphonates on bone
• Determinants of peak bone mass
- Normocalcemic hyperparathyroidism : study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism, 105(4). View this article in WRRO
- The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism : a systematic review and meta-analysis. Bone, 132. View this article in WRRO
- Quantitative computed tomography discriminates between postmenopausal women with low spine bone mineral density with vertebral fractures and those with low spine bone mineral density only: the SHATTER study. Osteoporosis International, 31(4), 667-675.
- The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone, 131, 115158-115158.
- Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone, 130.
- Association between drug treatments for patients with osteoporosis and overall mortality rates : a meta-analysis. JAMA Internal Medicine, 179(11). View this article in WRRO
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 104(5), 1595-1622.
- Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 124, 83-88.
- Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials. Journal of Bone and Mineral Research, 34(4), 632-642.
- Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. Journal of Bone and Mineral Research. View this article in WRRO
- Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporosis International. View this article in WRRO
- Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporosis International. View this article in WRRO
- Treatment‐Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti‐Resorptive Drugs: A Meta‐Regression. Journal of Bone and Mineral Research, 33(4), 634-642. View this article in WRRO
- Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood. Journal of Bone and Mineral Research, 30(5), 920-928. View this article in WRRO
- Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. The Lancet Oncology, 15(13), 1460-1468.
- Proton pump inhibitor use and the antifracture efficacy of alendronate.. Arch Intern Med, 171(11), 998-1004.
- Lasofoxifene in postmenopausal women with osteoporosis.. N Engl J Med, 362(8), 686-696.
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. NEW ENGL J MED, 361(8), 756-765.
- The effects of tibolone in older postmenopausal women. NEW ENGL J MED, 359(7), 697-708.
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.. J Clin Oncol, 26(7), 1051-1057.
- Effect of risedronate on the risk of hip fracture in elderly women. NEW ENGL J MED, 344(5), 333-340.
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. OSTEOPOROSIS INT, 11(1), 83-91.
- Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial.. BMJ, 315(7118), 1255-1260.
- Research group
- Professor Bo Abrahamsen
- Professor Nick Bishop
- Dr Dennis Black
- Dr Richard Jacques
- Professor Cyrus Cooper
- Dr Steven Cummings
- Dr Paul Dimitri
- Pefessor Claus Gluer
- Dr David Hughes
- Professor Eugene McCloskey
- Dr Paul Miller
- Dr Nicola Peel
- Professor Graham Russell
- Professor Mark Wilkinson
- Professor Graham Williams
- Ankita Duseja
- Patryk Zarecki
- Teaching interests
I teach medical students and oversee B. Med. Sci. projects. I teach on a number of postgraduate courses as well as giving invited lectures.
- Professional activities
I am an Emeritus Senior Investigator of the NIHR, a Fellow of the Academy of Medical Sciences. I am past president of the European Calcified Tissue Society, the Bone Research Society and past chairman of the National Osteoporosis Society. I am Senior Editor of the journal 'Bone'.